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Abstract  
Background/Aims: Clinical manifestations of Niemann Pick type-C1 (NP-C1) disease include 
neonatal hepatosplenomegaly, and in some patients progressive liver dysfunction and 
failure. This study involved a 
1
H-NMR linked metabolomics analysis of liver samples 
collected from a NP-C1 disease mutant mouse model in order to explore time-dependent 
imbalances in metabolic pathways associated with NP-C1 liver dysfunction, including 
fibrosis.  
 
Methods: NP-C1 mutant (Npc1
-/-
; NP-C1), control (Npc1
+/+
; WT) and NP-C1 heterozygous 
mice (Npc1
+/-
; HET) were generated from heterozygote matings. Aqueous extracts of these 
liver samples collected at time-points of 3, 6, 9 and 11 weeks were subjected to high-
resolution NMR analysis, and multivariate (MV) metabolomics analyses of datasets acquired 
were performed. 
 
Results: A MV random forests (RFs) model effectively discriminated between the NP-C1 and 
a combined HC/HET hepatic NMR profiles with very high predictive accuracy and reliability. 
Key distinguishing features included significant upregulations in the hepatic concentrations 
of phenylalanine, tyrosine, glutamate, lysine/ornithine, valine, threonine, and 
hypotaurine/methionine, and diminished levels of nicotinate/niacinamide, inosine, 
phosphoenolpyruvate and 3-hydroxyphenylacetate. Quantitative pathway topological 
analysis confirmed that imbalances in tyrosine biosynthesis, hepatic phenylalanine, tyrosine, 
glutamate/glutamine and nicotinate/niacinamide metabolism were involved in the 
pathogenesis of NP-C1 disease-associated liver dysfunction/damage.  
 
Conclusions: 
1
H NMR-linked metabolomics analysis provides valuable biomarker information 
regarding hepatic dysfunction or damage in NP-C1 disease.  
 
Keywords: NP-C1 Disease; Liver Damage/Dysfunction; Fibrosis-cirrhosis; NMR-Based 
Metabolomics; Biomarkers; Amino Acid Biosynthesis and Metabolism; Nicotinate and 
Niacinamide Metabolism; 3-Hydroxyphenylacetate; Metabolic Pathway Analysis.   
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1. INTRODUCTION 
 
Niemann-Pick type C (NP-C) disease is a neurodegenerative lysosomal storage disorder 
caused by mutations in the NPC1 or NPC2 genes, the hereditability of which is autosomal 
recessive.
1,2
 Approximately 95% of patients have mutations in the NPC1 gene (mapped to 
18q11) which encodes a large membrane glycoprotein primarily located in late endosomes 
(LEs) and lysosomes.
3
 The remaining 5% of mutations are in the NP-C2 gene (mapped to 
14q24.3), which encodes a small soluble lysosomal protein that binds cholesterol in the 
lysosomal lumen.
3
 Patients affected by NP-C1 or NP-C2 diseases are indistinguishable, both 
clinically and in terms of any standard biochemical evaluations available for NP-C disease 
diagnosis.
4
 
 
Dysfunction of NPC1 or NPC2 proteins leads to a complex storage pattern of cholesterol and 
sphingolipids in late endosomes/lysosomes. Progressive neurodegeneration, together with 
liver and lung disease are characteristic symptoms.
5
 Liver disease features, such as 
cholestasis with neonatal jaundice, together with hepatosplenomegaly, are usually 
encountered in the early stages of the disease; indeed, in some patients these symptoms 
become chronic and hence fatalities from liver failure occur.
6
 The pathophysiology 
associated with NP-C1 disease-associated liver dysfunction are of much importance, since 
this organ plays a central role in maintaining whole-body cholesterol and lipoprotein 
metabolism.
7
 Several studies in NP-C1 mice suggest that hepatocyte apoptosis may 
represent a primary cause of liver dysfunction and failure.
8,9
 Moreover, an increased 
activation of macrophages serves as a further cause of progressive liver degeneration in this 
animal model.
10
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Metabolic profiling of biofluids and/or tissues by high-resolution NMR analysis has been 
successfully applied to explore the pathogenesis of a wide range of clinical conditions,
11-13
 
and recent investigations have demonstrated the utility of this technique for the 
investigation of NP-C disease.
14,15
 Moreover, a multivariate genomics approach has been 
employed for seeking biomarkers for NP-C1 disease in serum.
16
 NMR-linked metabolomics 
analysis can provide a complete evaluation of low-molecular-mass metabolites present in 
the hepatic tissue of experimental animal models, and in this context offers potential for the 
provision of valuable metabolic profiling information.
17
 This strategy offers major 
advantages over many conventional bioanalytical approaches for the evaluation of liver 
disease, which provide information regarding the concentrations of perhaps only several 
biomarkers, and which are therefore insufficient for the provision of a global metabolic 
characterisation for comparative classification purposes.  
 
In this investigation, we report for the first time a 
1
H NMR-linked metabolomics 
investigation of the biomolecular profiles of liver specimens collected from NP-C1 disease-
active, age-matched heterozygous NP-C1 carrier, and healthy control mice in an established 
animal model system.
18
 For this purpose, we employed a cross-validated Random Forests 
(RFs) model, together with further multivariate (MV) analysis strategies. Npc1-null mutant 
mice (Npc1
−/−
) serve as a valuable model system for exploring the impact of Npc1 deficiency, 
and features a range of the biochemical, pathological, neurological and behavioural 
characteristics of human NP-C disease (these include the storage of unesterified cholesterol 
and sphingolipids, Purkinje cell loss, axonal swelling, neuronal vacuoles and progressive 
motor impairments such as tremor, ataxia, and loss of co-ordination;
19-21
 subsequent to a 
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progressive body weight loss, these mice die at ages of 10-12 weeks
20
). In order to 
investigate the onset and progression of hepatic pathology in Npc1-deficient mice, liver 
samples of NP-C1 mutant mice, and age-matched heterozygous carriers, and controls, were 
examined at 4 time-points during their life span, i.e. those corresponding to pre-
symptomatic (3 weeks), early symptomatic (6 weeks) and late symptomatic (9 weeks) and 
end stage (11 weeks) criteria.  
 
The biochemical and metabolic significance of the results acquired were further analysed 
and evaluated via the application of quantitative metabolite set enrichment and metabolic 
pathway topological analysis. The potential clinical significance of the results in relation to 
NP-C1-associated liver dysfunction are discussed in detail.   
 
2. MATERIALS AND METHODS 
 
2.1 Experimental animals: A spontaneous mutant mouse model of NPC on a BALB/C 
background was employed (Npc1
−/−
).
20
 NP-C1 mutant (BALB/cNctr-Npc1m1N/J, Npc1
-/-
; NP-
C1), control (Npc1
+/+
; WT) and NP-C1 heterozygous mice (Npc1
+/-
; HET), were generated 
from heterozygote matings. The wild-type littermates (+/+) were used as 
controls. Genotyping of NP-C1 mice was determined by polymerase chain reaction (PCR) as 
described previously.
22
 Mice were bred and housed under standard sterile conditions at the 
University of Oxford. All animal procedures were conducted using protocols approved by 
the UK Animals (Scientific Procedures) Act (1986). The Npc1
-/-
 mice have a lifespan of 10-12 
weeks (mean 10.5 weeks), with neurological symptoms presenting from 5-6 weeks of age. In 
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total, 89 liver samples from gender-matched heterozygous carrier (HET), NP-C1 disease (NP-
C1) and WT mice were collected at time-points of 3, 6, 9 and 11 weeks (Table 1).  
 
2.2 Extraction of aqueous metabolites for 
1
H NMR-linked metabolomics analysis: The 
extraction protocol employed was based on the procedure described by Waters et al.
23
 A 
portion of hepatic tissue (ca. 80 mg) from each liver sample was accurately weighed, and an 
ice-cold extraction solvent (1:1 H2O:CH3CN) was then added at a volume equivalent to 20 μL 
per mg of tissue. Subsequently, the sample was mechanically homogenised using an electric 
pestle rotor (Sigma-Aldrich, UK), and the homogenates were then centrifuged at 10,000 × g 
for a period of 10.0 min. at 4°C. 1.00 mL volumes of each supernatant (containing 
hydrophilic metabolites) were lyophilised and then reconstituted in 500 µL of D2O 
containing 0.05% (w/v) sodium 3-trimethylsilyl-(2,2,3,3-
2
H4)-1-propionate (TSP, chemical 
shift reference and internal quantitative 
1
H NMR standard) and 50 µL of a 1.00 M solution of 
phosphate buffer (pH 7.00). Subsequently, samples were thoroughly rotamixed and 
centrifuged at 5,000 x g for 5.0 min. at ambient temperature, and the clear supernatants 
transferred to 5-mm NMR tubes for analysis.  
 
2.3 
1
H NMR analysis: Single-pulse 
1
H-NMR spectra were acquired on a Bruker Avance AM-
400 spectrometer (Leicester School of Pharmacy facility, DMU, Leicester, UK) operating at a 
frequency of 399.94 MHz and a probe temperature of 298 K. These spectral acquisitions 
involved the noesygppr1d (TOPSPIN version 3.0, Bruker Biospin) pulse sequence for water 
suppression. For each spectrum, 128 scans were acquired, with a relaxation delay of 3 s, a 
spectral width of 4,800 Hz and a time domain of 32 K points. Spectra were acquired in an 
automated manner using a sample changer for continuous sample delivery. 
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Spectra were phased and baseline-corrected using ACD/labs Spectrus Processor 2013, and           
an exponential line-broadening function of 0.30 Hz was applied. Subsequently, the 
intelligent bucketing procedure was employed, giving a dataset of 89 rows (samples) and 
175 columns (potential predictor variables). The resulting intelligently-selected bucket (ISB) 
integral intensity values were normalised to the TSP internal standard signal (s, δ = 0.00 
ppm). Spectral regions which did not contain any resonances were removed, yielding a final 
dataset of 89 (samples/rows) x 136 (variables/columns) for further analysis. The intense δ = 
4.65-5.16 ppm residual H2O/HOD signal region was also removed from all the 
1
H NMR 
profiles acquired prior to the performance of MV data analysis strategies.  
 
2.4 Metabolite Identification: 
1
H-NMR spectra were assigned on the basis of literature 
values,
17,24
 available databases (HMDB),
25
 and by the consideration of chemical shift values, 
coupling patterns and coupling constants. The two-dimensional (2D) NMR techniques 
1
H-
13
C 
HSQC (heteronuclear single quantum correlation) and 
1
H-
1
H COSY (correlation spectroscopy 
were employed for structural confirmation purposes. HSQC and COSY spectra were acquired 
on the above Bruker Avance AM-400 spectrometer. For the HSQC experiments, the 
hsqcedetgpsp.3 pulse sequence (TOPSPIN version 3.0, Bruker Biospin) was employed, and 
256 scans for 128 increments were acquired for each spectrum. The F2 and F1 spectral 
widths were 6,340 and 16,600 Hz, respectively. COSY spectra were acquired using the 
cosygpprqf pulse sequence (TOPSPIN version 3.0, Bruker Biospin), recording 48 scans. The 
spectral width was 4,000 Hz. 
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2.5 Data Processing, Univariate and Multivariate Analysis: The integral values obtained 
from the ISB procedure outlined in section 2.3 were cube root-transformed and Pareto-
scaled in order to satisfy assumptions of normality and homogeneity of intra-sample 
variances, which is a stringent requirement for the additional statistical analysis strategies 
subsequently applied, including analysis-of-covariance (ANCOVA), together with ANOVA-
Simultaneous Component Analysis (ASCA).
26
 Nevertheless, since the RFs technique has a 
non-parametric basis, it is generally unaffected by such feature scaling. 
 
The experimental design for univariate analysis of the 
1
H NMR ISB intensity datasets 
involved an ANCOVA model, which incorporated 3 factors and 6 primary sources of 
variation: (1) 'between-disease classifications’ (qualitative NP-C1 disease-active vs. the 
combined HET/WT control group), fixed effect (Di); (2) ‘between-genders’ fixed effect 
(qualitative) 'nested' within 'disease classifications' (Gj); (3) the experimental sampling time-
point fixed effect (quantitative, Tk); (4, 5 and 6) disease classification x gender, disease 
classification x time-point and gender x time-point first-order interaction components (DGij, 
DTik and GTjk) respectively. This experimental design is represented by equation 1, in which 
Yijk represents the (univariate) ISB predictor variable values observed, μ its overall 
population mean value in the absence of any significant, influential sources of variation, and 
eijk the unexplained error (residual) contribution. 
 
Yijk = μ + Di + Gj + Tk + DGij + DTik + GTjk + eijk                                                                                                                               (1) 
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ANCOVA was conducted with XLSTAT2014. ASCA, principal components analysis (PCA) and 
partial least-squares discriminatory analysis (PLS-DA) were applied using MetaboAnalyst 
3.0.
27
 
       
RFs analysis was employed for classification and variable selection purposes using the 
RandomForest R package.
28
 RFs analysis was applied over 100 iterations. For each     
iteration, the mean and standard error (SEM) of the out-of-the-bag (OOB) error, and 
confusion matrix were computed. For each of the 100 iterations performed 33% of the 
samples were included in the test-set, whilst the remaining 67% served as the training-set. 
For variable selection purposes, the variable importance parameter values for the 136 
variables were estimated using the mean decrease in accuracy (MDA) value, since this index 
has been suggested to be the most reliable metric for this purpose.
29,30
 Further details 
regarding the RFs approach employed here are available in section S1. 
 
The RFs model was tuned for the analysis of the NP-C1 vs. the combined Het/WT 
classifications (based on the OOB error value obtained in order to improve its performance), 
so that optimal mtry (number of variables selected for splitting at each node involved), and 
ntree (number of trees) values were selected to be 11 and 1,000 respectively. 
 
In order to evaluate the ability of the RFs technique to classify and predict, a Receiver 
Operating Characteristic (ROC) curve analysis was also performed using the MetaboAnalyst 
ROCCET option available.
31
 Further validation was performed with XLSTAT2015, which 
employed permutation testing via partial redundancy analysis (P-RDA), with gender and 
sampling time-point as the ‘conditioning’ variables, and 5 x 10
4
 permutations. 
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2.6 Quantitative Metabolic Pathway Topological Analysis: Detailed analysis of the most 
relevant hepatic metabolic pathways and networks involved in the pathogenesis of NP-C1 
disease was performed by MetaboAnalyst 3.0 tools.
27
 For this dataset, we employed the 
Global ANCOVA and Relative-Betweeness Centrality algorithm for metabolic pathway and 
topological analyses, the latter serving as a key measure indicating the importance of a 
graph node when expressed relative to that of the others.
32
 For the quantitative pathway 
topological analysis performed, the mus musculus (mouse) mammalian pathway library was 
selected. This approach was also utilised to provide estimates of pathway impact and false 
discovery rate (FDR)-adjusted p values. 
 
3. RESULTS 
 
3.1 
1
H NMR Profiles of liver samples collected from NP-C1 disease, heterozygous carrier 
and wild type mice: Typical 400 MHz 
1
H NMR spectra of aqueous extracts of liver samples 
collected from NP-C1 disease mice (Figure 1), together with corresponding heterozygous 
carrier (HET) and healthy control (WT) specimens contained a large number of prominent 
resonances assignable to a wide range of low-molecular-mass metabolites, including amino 
acids, organic acid anions, carbohydrates and nucleotides. 
 
The acquisition of 2D 
1
H-
13
C HSQC and 
1
H-
1
H COSY NMR techniques readily confirmed the 
structural identities of many of the resonances present in the 1D 
1
H NMR profiles of the liver 
sample aqueous extracts (a full list is provided in Table S1). In total, greater than 40 
metabolites were unambiguously assigned by the employment of combinations of two or 
more of these 1D and 2D bioanalytical NMR strategies.  
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The assignment of phenylalanine, tyrosine, nicotinate and niacinamide (nicotinamide) was 
facile since their 
1
H NMR signals are clearly visible in unobscured regions of the 1D 
1
H NMR 
spectra acquired, and in some cases further supporting evidence for such assignments was 
obtained, since two or more resonances arising from individual metabolites were indicated 
as discriminatory variables. However, application of 2D-NMR experiments was required to 
confirm assignments of the valine resonances since they are located at chemical shift values 
close to those of leucine and isoleucine. Additionally, both methionine and hypotaurine 
have triplet resonances located at ca. 2.65 ppm, coupled to a multiplet located at 2.15 ppm 
for the former, and a triplet at 3.35 ppm for the latter; both these linkages were observed in 
the 2D COSY NMR experiments conducted (Figure S2). The 3-hydroxyphenylacetate 
resonance was detectable, at low intensity, in 23 of the HET and WT liver samples, but only 
in 4 of the NP-C1 samples, specifically the 6.78-6.81 ppm ISB; generally, an uncrowded 
region for all the tissue spectra acquired. Similarly, the phosphoenolpyruvate (PEP)-CH2a 
resonance was readily visible, as was inosine’s purine ring-C2-CH signal (s, δ = 8.35 ppm), 
which also served as a significant discriminatory feature in the experiments conducted. 
 
Assignments for the aspartate and glutamate resonances were also confirmed by such 2D-
NMR experiments. The ABX coupling system of the C2-CHb proton resonance of aspartate 
lies within the 2.79-2.81 ppm ISB. For the combined lysine /ornithine ISB resonances (δ = 
1.70-1.74 and 2.99-3.05 ppm), 
1
H-
13
C HSQC spectra acquired confirmed the identities of 
these amino acids, and hence this 
1
H NMR ISB did not arise from further metabolites with 
similar δ values (for example, putrescine and spermidine). 
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3.2 Preliminary Multivariate Exploratory Data Analysis: Preliminary PCA and cross-
validated (CV) PLS-DA MV analyses conducted revealed that the most important 
discriminatory metabolic ISB variable features predominantly comprised resonances arising 
from amino acids and nucleotide metabolites. Indeed, both these forms of analysis revealed 
that there was a significant clustering of the NP-C1 disease classification which was distinct 
from both the HET and WT groups; however, no discrimination between the latter two 
disease status classifications were found. Indeed, with this unsupervised PCA approach, the 
3D component 4 vs. component 3 vs. component 2 scores plot [Figure 2(a)] provided the 
best visualisation of this NP-C1 vs. the combined HET/WT group discrimination. The NP-C1 
cluster exhibited lower scores vectors than those of the combined HET/WT ones for 
components 3 and 4; there appeared to be no ‘between-classification’ differences between 
these scores vectors for component 2, as notable from projections of the 3D plot on the 2D 
planes. 
 
3.3 RFs strategy for classification purposes: As noted above, primarily the 3 classification 
groups (i.e. NP-C1, HET and WT) were analysed. The RFs MV analysis strategy performed for 
direct comparisons of the HET vs. WT classifications resulted in an OOB error value of 0.459 
(SEM = 0.00061), suggesting no significant differences between these groups. However, 
significant values for the OOB error term were obtained when the RFs approach was 
employed for comparisons of the NP-C1 vs. HET, and NP-C1 vs. WT control groups [OOB 
error values of 0.146 (SEM = 0.00019) and 0.230 (SEM = 0.00023) respectively]. For these 
analyses, the NP-C1 vs. HET group comparison yielded predictive accuracies of 76.2, 79.8, 
82.1, 84.9, 87.4 and 87.8% for models with a maximum of 5, 10, 15, 25, 50 and 100 variables 
respectively (corresponding AUROC values were 0.840, 0.893, 0.913, 0.929, 0.953 and 0.960 
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respectively), whereas for the NP-C1 vs. WT group comparison, these results demonstrated 
predictive accuracies of 75.1, 77.2, 78.9, 80.6, 81.6 and 81.0% for models with 5, 10, 15, 25, 
50 and 100 variables respectively (corresponding AUROC values were 0.819, 0.851, 0.866, 
0.885, 0.892 and 0.898 respectively). Hence, there was a marginally improved level of 
discrimination achieved in the NP-C1 disease vs. HET comparison over that of the NP-C1 vs. 
WT one (Figure S1). 
 
These results are consistent with those arising from the PCA results described above. In view 
of these observations, the HET and WT groups were combined (and labelled HET/WT) for 
further analysis. When applied to these alternative sample groupings, this RFs approach 
gave an OOB error value of 0.156 ± 0.00013(mean ± SEM). For predictive performance, 
values for sensitivity, specificity and accuracy were 0.84 ± 0.00069, 0.89 ± 0.0017 and 0.85 ± 
0.00050 respectively. The classification performance of this RFs model is exhibited in Figure 
2(b). 
 
We also elected to perform the PLS-DA and orthogonal PLS-DA (OPLS-DA) techniques in 
order to directly compare the 3-week time-point dataset with that of the 9-week one for 
both the NP-C1 and HET/WT disease classification groups. Indeed, a PLS-DA model featuring 
4 sub-groups (specifically the 3- and 9-week time-points only for both the NP-C1 disease and 
HET/WT control groups) demonstrated that the 9-week (late stage) NP-C1 disease group 
formed a cluster that was clearly distinct from that of the 3-week (pre-symptomatic) NP-C1 
disease one, together with those of both the 3- and 9-week time-points of the HET/WT 
classifications, the latter two being indistinguishable [Figure 3(a)]. For this approach, a 
maximum Q
2
 value of 0.534 was obtained for a model featuring 5 components, and model 
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validation performed by permutation testing (with 2,000 permutations) based on separation 
distance gave a highly significant p value of 0.0045. Key biomarker features responsible for 
the discrimination of the 9-week NP-C1 disease classification from the 3- and 9-week 
HET/WT one were the upregulated valine, phenylalanine, threonine resonances, in addition 
to the combined hypotaurine/methionine one [Variable Importance Parameter (VIP) values 
ranged from 1.41-1.74]. 
Similarly, an O-PLS-DA analysis [Figures 3(b) and (c)] confirmed the significance of the 
upregulated valine, phenylalanine and threonine predictor variables, and also provided 
supporting evidence for the involvement of downregulated PEP, 3-hydroxyphenylacetate, 
and the unassigned 0.77-0.80 ppm resonance as significant biomarker features (these 
predictors were isolated via a scrutinization of the O-PLS-DA S-plot). This O-PLS-DA analysis 
was also validated through permutation testing (2,000 permutations), and the Q
2
 and R
2
Y 
values of 0.534 and 0.812 were very highly significant (p = 5.00 x 10
-4
 for both parameters).    
3.4 Variable selection: The top 15-predictor variable features from the RFs analysis, 
together with their respective rankings and assignments are shown in Table 2. These 
variables included significantly elevated hepatic spectral intensities of key amino acids 
(phenylalanine, tyrosine, glutamate, lysine/ornithine, hypotaurine/methionine, threonine 
and valine), along with reduced ones for nicotinate/niacinamide, 3-hydroxyphenylacetate, 
inosine, PEP and an unassigned species with a triplet resonance located within the 0.77-0.80 
ppm ISB. Whilst this latter resonance remains unassigned, 
1
H-
1
H COSY NMR analysis 
demonstrated that this triplet signal was linked to a multiplet centred at δ = 1.99 ppm 
(Figure S2), an observation indicating that the latter is attributable to a proton located α- to 
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a carboxylate function, i.e. these coupled resonances appear to arise from a carboxylic acid 
anion species.  
 
Although the unassigned 0.77-0.80 ppm ISB variable was not found to be significant in a 
univariate context, it should be noted that multivariate (MV) analysis strategies make use of 
all variables simultaneously, and therefore focus on simultaneous relationships, linear or 
otherwise, amongst all available variables. Indeed, these approaches focus on 
covariances/correlations between these variables, i.e. they reflect the extent of these 
relationships between potentially large numbers of variables, unlike univariate methods 
which simply consider the mean and variance values of single variables.   
3.5 Investigations of potential ‘between-gender’ and ‘between-sampling time-point’ 
variance component contributions: For further investigation of the potential ‘between-
gender’ component of variance contribution to the MV dataset, the RFs procedure outlined 
above was again applied, but in this case with gender as the classification criterion. This 
analysis was performed in order to confirm that the gender variance contribution was not 
significant, i.e. that it did not condition the disease biomarker variables selected. Since the 
OOB error value obtained was 0.44 (SEM = 0.000423) [accuracy (SEM) = 0.54 (0.000837); 
sensitivity (SEM) = 0.55 (0.00238), specificity (SEM) = 0.56 (0.00138)], this confirmed that 
the significant metabolite differences observed were not influenced by this variance 
component. 
 
Collection time-points were investigated using an ASCA time series analysis option. No 
significant differences were observed ‘between-time-points’ after performing this analysis 
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(p = 0.091), although this value was close to attaining statistical significance; furthermore, 
the ‘disease classification x time-point’ interaction component of variance was also found 
not to be significant for the first two (major) PCs explored (p = 0.198). However, as expec-
ted, the ‘between-diseases’ factor was indeed significant (p = 0.006). Moreover, the P-RDA 
approach, which involved the removal of any contributory effects exerted by the 
quantitative time-point and qualitative gender ‘conditioning’ variables confirmed the 
significance of the ‘between-diseases’ variable (p = 0.0032). This strategy was also applied to 
explore the contributions of gender and experimental sampling time-point variables (with 
the effects exerted by combinations of the disease classification/sampling time-point and 
disease classification/gender factors, respectively, removed as ‘conditioning’ variables) 
revealed that the time-point variable was indeed significant (p = 0.022), as expected, 
whereas that ‘between-genders’ was not (p = 0.136).   
 
Since several of the biomolecules identified from this RFs analysis had >1 discriminatory ISB 
variable, in such cases only ISBs with the highest MDA values for that biomolecule were 
retained in order to explore the time dependency of the variables. Therefore, the top 15 ISB 
features were reduced to 12 key biomarkers (or combinations of them in cases where ISBs 
contained resonance contributions from 2 such metabolites). Plots of mean (± SEM) 
normalised ISB intensity values vs. collection time-point for those 12 discriminatory 
metabolites selected by the RFs model are shown in Figure 4. Lower ISB intensity values for 
valine, glutamate, hypotaurine/methionine, threonine, tyrosine, lysine/ornithine and 
phenylalanine were observed at the week 3 time-point than those at subsequent ones for 
the NP-C1 disease classification, and these observations appear to be consistent with the 
pre-symptomatic nature of this time-point, i.e. elevated levels of these biomolecules appear 
Page 16 of 65
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17 
 
at the early (6 week) and late (≥ 9 week) symptomatic time-points. However, there 
appeared to be no significant time-dependence of hepatic 3-hydroxyphenylacetate and PEP 
levels. It is clear from these plots that there were elevated concentrations of valine, 
glutamate, hypotaurine/methionine, lysine/ornithine, threonine, tyrosine and phenylalanine 
for the NP-C1 disease classification over those of the combined HET/WT group at all the 
post-symptomatic time-points, together with lower ones for 3-hydroxyphenylacetate (with 
the exception of the week 6 time-point samples for this metabolite) and the combined 
nicotinate/niacinamide variable in this group. Although the admixed nicotinate/niacinamide 
ISB intensity decreased with increasing time-point for the NP-C1 disease group, such 
differences were not statistically significant. For the NP-C1 disease classification, the valine, 
glutamate, tyrosine, phenylalanine, hypotaurine/methionine, lysine/ornithine and threonine 
predictor biomarker variables all reach maximal levels at week 11.  
 
The univariate ANCOVA model revealed a significant time-point-dependency of some 
metabolites, particularly phenylalanine (p = 0.019), tyrosine (p = 2.47 x 10
-3
), valine (p = 3.28 
x 10
-4
), 3-hydroxyphenylacetate (p = 2.24 x 10
-3
), threonine (p = 4.56 x 10
-4
) and 
lysine/ornithine (p = 3.17 x 10
-4
). Additionally, this ANCOVA strategy also provided 
significant p values for the ‘between-gender’ factor for phenylalanine (p = 0.019), tyrosine (p 
= 0.014), valine (p = 0.028) and threonine (p = 0.015); these four metabolites showed 
marginally higher levels for male mice. The combined ‘time-point x disease classification’ 
interaction effect was significant for hypotaurine/methionine (p = 0.017) and inosine (p = 
0.046), and that for the combined ‘gender x disease classification’ effect was significant for 
phenylalanine (p = 0.040), tyrosine (p = 0.036), 3-hydroxyphenylacetate (p = 0.014) and 
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lysine/ornithine (p = 0.047). However, these p values were uncorrected for false discovery 
rate (FDR).  
 
Performance of the above RFs model, but excluding the pre-symptomatic week 3 samples, 
gave rise to a slight improvement compared to that achieved without removal, i.e. a mean 
OOB error value of 0.16 ± 1.47 x10
-4
, and prediction performance values for accuracy, 
sensitivity and specificity of 0.84 ± 7.03 x10
-4
, 0.84 ± 8.76 x10
-4
 and 0.88 ± 2.82 x10
-3
 
respectively. Additionally, SEM values estimated for all of these parameters were found to 
be lower in this improved model; these results are consistent with the pre-symptomatic 
nature of samples collected at the week 3 time-point in NP-C1 mice.  
 
3.6 ROC analysis: In order to evaluate the ability of our RFs model to classify and predict 
disease classification status using these 
1
H NMR ISB biomarker variables, a ROC analysis was 
performed. With the 12 key biomarker variables selected above (attributable to 
phenylalanine, tyrosine, valine, methionine/hypotaurine, niacinamide/nicotinate, 
lysine/ornithine, threonine, glutamate, PEP, inosine, 3-hydroxyphenylacetate and the 
unassigned 0.77-0.80 ppm ISB), this RFs approach gave a maximum AUROC value of 0.941 
(95% CI = 0.823-0.987), and predictive accuracies of up to 85.5% [Figure 5(b)]. For this 
purpose, the entire dataset was permuted to generate different RFs models containing 
increasing numbers of variables from those available, and total numbers of 2, 3, 5, 7, 10 and 
12 predictor variables were employed for constructing them. The employment of 12 
variables in total was found to provide a highly effective level of discrimination between the 
two classification groups explored [Figure 5(a)].  
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Key discriminatory biomarker variables featured in the NP-C1 vs. HET comparison were 
phenylalanine > GSSG > valine > tyrosine > lysine/ornithine > PEP > creatine > hypotaurine/ 
methionine > unassigned 0.77-0.80 ppm resonance > threonine, whereas those for the NP-
C1 vs. WT comparison were tyrosine > phenylalanine > hypotaurine/methionine > valine > 
threonine > glutamate > lysine/ornithine > GSSG > creatine.   
3.7 PCA and PCA loadings of the 12 selected biomarker variables: PCA was also applied to 
this 12 variable dataset [Figure 6(a)], and results acquired clearly confirm a high level of 
distinction between these two disease group classifications when using this set of 
biomarkers. Interestingly, the loadings of these 12 variables revealed a cluster containing 
the majority of the amino acid biomarkers, with higher positive loadings for PC1 [PC1 
loadings ranged from 0.27 (phenylalanine) to 0.43 (valine)] and negative ones for PC2. The 
0.77-0.80 ppm bucket has PC1 and PC2 loading values very similar to those of PEP, i.e., high 
loadings for PC2 and intermediate ones for PC1 [Figure 6(b)]. Inosine, together with the 3-
hydroxyphenylacetate and combined nicotinate/niacinamide signal had relatively high PC2 
and low or negative PC1 loadings; a repeat PC loadings analysis also containing individual, 
isolated nicotinate and niacinamide signals (δ = ppm respectively) demonstrated that both 
these metabolites had very similar PC1 and PC2 loadings to the combined 
nicotinate/niacinamide one employed in this model). However, hepatic threonine 
concentrations appear to be unrelated to the above clusters. Contributions towards higher 
PCs (PC3, PC4, etc.) were negligible in this model. 
 
Similarly, PLS-DA was employed for the analysis of this dataset containing 12 predictor 
variables, and both Q
2
 and predictive accuracy values obtained (0.62 and 0.92 respectively) 
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were the highest for a model system incorporating four components (components 1-4); 
these quality measures were not significantly improved by the inclusion of one or more of 
components containing further metabolic predictor variables. 
 
3.8 Glutathione (GSH/GSSG) redox status of the NP-C1 and HET/WT classifications: 
Although not featuring as significant biomolecule variables in the RFs and further MV 
analysis models developed, we also explored differences between the mean hepatic 
concentrations of glutathione (GSH) and its corresponding disulphide oxidation product 
(GSSG), and in particular that of the [GSH]:[GSSG] concentration ratio, between the NP-C1 
and HET/WT classifications investigated. Primarily, it was found that hepatic GSH levels 
were significantly reduced in NP-C1 mice (p = 0.019), although no such differences were 
noted for GSSG (Figure S3). However, there was a much more highly significant decrease in 
the mean [GSH]:[GSSG] ratio of the NP-C1  group when compared to that of the HET/WT 
control one (p = 0.0076).    
 
3.9 Metabolic Pathway Analysis: Quantitative mouse pathway topological analysis revealed 
significant NP-C1 disease-mediated imbalances in tyrosine biosynthesis and metabolism, 
phenylalanine metabolism, taurine and hypotaurine metabolism, arginine and proline 
metabolism, nicotinate and niacinamide metabolism, and glycolysis or gluconeogenesis 
(specifically reaction steps involving PEP), in addition to perturbations in those featuring 
glutathione and purine (downregulated inosine) metabolism, as listed in Table 3.  
 
 
Page 20 of 65
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21 
 
Disturbances to the metabolism of at least some of the above amino acids appear to be 
common to experimental models of liver fibrosis,
33,34
 and the livers of mutant NP-C1 disease 
mice become progressively fibrotic in the mouse model employed here
35
 (discussed in 
section 4.2 below).    
 
4. DISCUSSION 
 
4.1 Multicomponent 
1
H NMR analysis of mouse liver samples: The 
1
H NMR profiles of 
mouse liver samples acquired here contained a wide range of metabolites arising from a 
series of hepatic metabolic processes. Many of the assignments made in the spectra 
acquired were routinely supported and confirmed via the application of 2D NMR 
bioanalytical strategies, in particular the 
1
H-
13
C HSQC and 
1
H-
1
H COSY techniques. In this 
manner, we were able to confirm the identities and quantitate a total of more than 40 
hepatic biomolecules (Table S1).  
 
Preliminary analyses revealed no significant differences in the 
1
H NMR profiles of liver 
samples collected from WT and HET mice. In addition, no time-dependent or gender-specific 
variance in hepatic metabolite levels was observed, and in view of this, the HET and WT 
groups were combined and further MV analysis was focused on comparisons of the 
combined HET/WT group profiles to those of NP-C1 disease mice. The discriminatory 
variables identified by RFs analysis were selected amino acids, 3-hydroxyphenylacetate, 
niacinamide and nicotinate, PEP and inosine, together with an unassigned ISB (δ = 0.77-0.80 
ppm); the advantages of this approach are detailed in supplementary section S1.  
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4.2 Relevance to liver fibrosis-cirrhosis development: Livers from NP-C1 mice exhibit an 
elevated level of fibrosis, together with hepatocyte apoptosis, inflammation, the infiltration 
of foamy macrophages, and proliferation of hepatic stellate cells.
8,9,36
 Of these processes, 
fibrosis plays a predominant role, and is characterised by the replacement of liver tissue by 
fibrous scar tissue, in addition to regenerative nodules (cirrhosis, which is responsible for 
major alterations to liver tissue, represents the irreversible end-stage of these 
developments). Hence, fibrosis gives rise to a progressive loss of liver function, and to a 
modified liver metabolism.
37-40
 Taken together, collagen and hydroxyproline levels serve as 
valuable hallmarks for liver fibrosis, the latter as an index of collagen metabolism.
41
      
 
Currently, reports on biochemical and metabolomics investigations of the development of 
liver fibrosis, and subsequently cirrhosis, in animal models and humans (
1
H NMR-based or 
otherwise) are limited. However, during the induction of fibrosis-cirrhosis with 
thioacetamide (TAA), Constantinou et al.
33
 found significant elevations in the hepatic levels 
of glutamate/glutamine, proline and choline, observations coupled with corresponding 
decreases in those of acetate, fumarate, TMA, glycogen and inosine. Moreover, in a similar 
TAA-based animal model, Waters et al.
34
 reported significant elevations in the liver contents 
of the amino acids isoleucine, leucine, methionine, histidine, phenylalanine and tyrosine, 
together with increases in those of inosine, adenine, uracil, formate, NMN, creatine, GSH, 
choline/phosphocholine, and lipids in general; these observations were accompanied by 
corresponding decreases in TMAO, betaine, glycogen, glucose and niacinamide 
concentrations. Hence, results from these studies are consistent with the upregulations of 
hepatic phenylalanine, tyrosine, glutamate and methionine, and downregulations in 
niacinamide observed in this study. Although the significantly diminished inosine levels 
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observed in our NP-C1 disease group are in accordance with the findings in
33
, this 
observation contrasts with that found in
34
. 
However, in a HR-MAS NMR investigation of human liver tissue samples collected by needle 
biopsy performed by Martinez-Granados et al.
42
 found upregulations of glutamate, 
phosphocholine and phosphoethanolamine, coupled with lower concentrations of choline, 
TMAO, glucose, glutamine, aspartate and unsaturated fatty acids in cirrhotic livers when 
expressed relative to those of non-cirrhotic ones, although it should be noted that such 
differences were only weakly significant in a univariate context (i.e., the p values provided 
were not corrected for multiple comparisons). Interestingly, glutamate was also featured as 
a top-15 variable by our RFs MVA, results revealing a significant increase in its hepatic level 
(p = 0.0010 from the ANCOVA model applied).   
Moreover, 
1
H NMR-detectable hydroxyproline was not found to represent a significant 
hepatic biomarker for the NP-C1 disease group in this study, and nor was it in any of the 
above fibrosis/cirrhosis-focused NMR investigations. 
In a further study, Rajendraa et al.
43
 explored modifications to the hepatic concentrations of 
free amino acids induced by repeated administration of hexachlorophene (HCP) to male 
adult mice; this agent exerts pathological modifications to liver structure and morphology 
(particularly enlargement of bile canaliculi, increases in gap junction numbers, and a 
disorganisation of tight junctions, together with mitochondrial lesions).
44
 These researchers 
found that phenylalanine, tyrosine, leucine, isoleucine, valine, threonine, asparagine, 
glutamate and glutamine levels were significantly elevated following HCP intoxication, 
whereas that of aspartate was markedly decreased (alanine, glycine, serine and taurine 
concentrations were unaffected). Moreover, reductions in the specific activity patterns of 
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enzymes involved in amino acid metabolism, i.e. those featuring aminotransferases and 
glutamate dehydrogenase, indicated a suppression of liver amino acid oxidation. The 
abnormal upregulations in branched chain and aromatic amino acids observed were 
ascribed to a reduced catabolism in view of a depleted skeletal muscle mass, and hepatic 
dysfunction respectively; these phenomena may also account for the upregulated liver 
valine and phenylalanine/tyrosine concentrations observed in this study. 
Alam et. al.
45
 monitored a series of inflammatory and fibrosis biomarkers in the livers of 
Npc1
-/-
mice, together with linked histological evaluations, and found that expression of the 
inflammatory genes Cd68 and Itgax (markers of macrophage, and activated macrophage, 
granulocyte and dendritic cells respectively) were upregulated ca. 88- and 400-fold, 
respectively, at the late (i.e. 70-83 days post-induction) disease stages. Furthermore, the 
Colal (procollagen type a1) marker, which is known to be upregulated during liver fibrosis
46
, 
was elevated 1.3-fold in Npc1
-/-
mice. Additionally, a large number of large foamy 
macrophages with high cathepsin S precursor (CTSS) levels were found in the livers of 80 
day aged Npc1
-/-
mice (unlike that of Npc+
-/-
mice), together with significant clusters of 
neutrophils.  
More recently, Alam et al.
47
 have reported that the Npc1
nmf164
 BALB/C mouse strain, which 
carries an aspartate-to-glycine mutation at position 105 (D1005G) in the Npc1 gene, 
displayed markedly elevated plasma levels of liver damage markers, specifically alanine and 
aspartate aminotransferases (ALT and AST respectively), along with much reduced total 
protein and albumin concentrations during the 100-day course of this model trial. These 
observations are, of course, consistent with liver fibrosis-cirrhosis development
48
.  
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A full summary of the biomarker status of the significant predictor metabolite variables 
detected in this investigation in fibrosis-cirrhosis development
33-35
, and also further liver 
disease/hepatic toxicity
43
, investigations reported is shown in Table 4. These results suggest 
that the lysine, ornithine, 3-hydroxyphenylacetate, and perhaps also PEP and nicotinate 
biomarkers discovered here may arise from the pathogenesis of NP-C1 disease rather than 
fibrosis-cirrhosis, or disease-unspecific liver failure. Therefore, further investigations are 
required to explore this.  
Moreover, a Venn diagram which depicts the similarities and differences in biomarker 
candidates found for NP-C1 disease mouse model liver, human and mouse model blood 
plasma/serum, and human urinary biomarkers between this study and those previously 
reported to date is displayed in Figure 7. This diagram reveals that upregulated valine and 
nicotinate levels were common to both NP-C1 mouse model system liver (this study) and 
human urine samples
14
, whereas previous investigations
49
 have detected elevated 
concentrations of monohexosyl ceramides in both mouse model liver and human blood 
plasma/serum for this disease. However, although sphingoid bases were found to be 
upregulated in NP-C1 mouse model liver samples, these levels were significantly diminished 
in human blood plasma
49
; indeed, there may be a significant inverse correlation between 
the blood plasma and liver levels of this biomarker in NP-C1 mice and/or humans.  
4.3 Upregulations of hepatic amino acids in NP-C1 mice: The results arising from the RFs 
and further MV statistical analyses conducted revealed that there were clear NP-C1-
mediated elevations in the concentrations of phenylalanine, tyrosine, lysine/orthinine, 
hypotaurine/methionine, glutamate, valine and threonine in NP-C1 disease mice. As noted 
above, these results are generally consistent with the time-dependent manifestation of liver 
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fibrosis in this animal model. Such metabolic modifications may be ascribable to muscle 
proteolysis, in addition to liver parenchyma necrosis.
50
 Moreover, imbalances in hepatic 
protein biosynthesis and necrosis-induced protein deterioration would also give rise to 
elevated free amino acid levels in both liver and blood plasma.   
 
The metabolic pathways of phenylalanine and tyrosine are linked through the action of 
phenylalanine hydroxylase, and the metabolism of both these aromatic amino acids (AAAs) 
occurs predominantly in the liver.
51
 Elevated blood plasma levels of phenylalanine, 
threonine, tyrosine, ornithine and methionine have been previously shown to serve key 
indicators of liver dysfunction and damage.
52,53
. Indeed, Fischer’s ratio [the molar ratio of 
branched-chain amino acids (BCAAs) to those of AAAs (specifically phenylalanine and 
tyrosine)] in blood plasma has been found to be of much value for evaluating liver 
metabolism, its dysfunctional severity and hepatic functional reserve. This ratio has long 
been employed for the analysis of free amino acid concentrations in liver diseases, and 
diminishes with hepatic damage severity.
54
 These modifications to plasma amino acid 
concentrations reportedly arise from an enhanced level of BCAA catabolism in muscle 
coupled with diminished AAA degradation in the failing liver.
55
 However, it should also be 
noted that plasma BCAA concentrations are critically dependent on nutritional factors, 
whereas it appears that corresponding AAA levels are determined by intact hepatic 
metabolism to a much greater extent. In addition, 
1
H NMR-based metabolomics studies 
have previously identified increased plasma amino acid levels in rats exposed to a 
hepatotoxin,
56
 and the detection of modifications to these plasma biomolecule 
concentrations in patients with liver diseases by this technique have been well documented, 
and are ascribable to impaired hepatic function, the portal-systemic shunting of blood, and 
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hyperinsulinaemia and hyperglucagonaemia.
57
 Hence, it appears that imbalances in liver 
amino acid contents observed here are linked to NP-C1-associated hepatic damage, 
including fibrosis.  Pathway topological analysis of the key biomarker dataset confirmed the 
critical importance of disturbances in tyrosine biosynthesis, together with hepatic 
phenylalanine and nicotinate/niacinamide metabolism in NP-C1 disease (Table 3).  
  
In humans, L-valine degradation, together with that of branched chain amino acids (BCAAs) 
in general, have been previously shown to be disturbed in two related studies focused on 
NP-C1 disease: firstly, in an 
1
H NMR metabolomics urinalysis study,
14
 and secondly in a 
microarray expression analysis of serum biomarkers.
16
 The upregulated hepatic valine levels 
found NP-C1 disease mice here, however, may be consistent with those of Ishigure et al.,
58
 
who found that human liver disease (specifically cirrhosis or hepatocellular carcinoma), 
diminishes the activities of methacrylyl-CoA hydratase and β-hydroxyisobutyryl-CoA 
hydrolase (enzymes involved in valine catabolism), and that decreased levels of these 
hepatic enzyme activities are derived from post-transcriptional regulation in the damaged 
liver.  
 
Increases in the plasma concentrations of methionine, together with additional amino acids 
(including alanine, glutamine and lysine) have also been observed in cases of hepatic 
failure,
59
 and our results indicate that hepatic methionine levels are also elevated in the 
mutant NP-C1 disease mouse model investigated. However, since the methionine-C4-CH2 
biomarker ISB signal observed here (δ = 2.62-2.67 ppm) overlapped with the more intense 
hypotaurine-CH2SO2
-
 resonance, additional experiments are required to explore this. 
Previous investigations have revealed that dietary agents containing methionine are 
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required for the maintenance of normal liver function.
60
 Therefore, any perturbations to 
methionine metabolism in our mouse model may indeed reflect NP-C1 disease-associated 
liver dysfunction, and hence there is a requirement for further investigations focused on this 
amino acid.    
 
4.4 Perturbations to nicotinate and niacinamide metabolites: Both niacinamide and 
nicotinate are major precursors of NAD
+
 and NADP
+
 synthesis in mammals, although NAD
+
 
can also be synthesized from amino acid precursors, most notably tryptophan (de novo 
pathway). 
 
In this NP-C1 disease mutant mouse investigation, a decrease in the hepatic 
1
H NMR ISB 
intensity of the 8.23-8.29 ppm ISB assigned to both nicotinate and niacinamide-C4-CH 
functions was observed. Indeed, a fold-change of -1.28  was noted for this ISB, and we have 
previously shown that metabolites in this pathway are downregulated in the urinary 
1
H 
NMR profiles of NP-C1 patients.
14
 In view of their roles as NAD
+
/NADH and NADP
+
/NADPH 
precursors, which are employed in a wide range of metabolic redox processes, these 
observations may be linked to highly significant biochemical and hepatocellular effects. For 
example, cytochrome P450 activity featured in microsomal oxidation systems are critically 
dependent on the NADP
+
/NADPH coenzyme system. Similarly, the NADP
+
/NADPH system is 
involved in the phenylalanine hydroxylase-mediated oxidative transformation of 
phenylalanine to tyrosine. A further example from BCAA catabolism involves the oxidative, 
irreversible decarboxylation of substrates to form branched-chain acyl-CoA adducts (a 
reaction catalysed by mitochondrial branched-chain α-keto acid dehydrogenase), which 
features the NAD
+
/NADH cofactor system.
61
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Also particularly noteworthy is the diminished mean hepatic concentration of GSH present 
in the NP-C1 mouse classification (section 4.6). These results may reflect a disease-mediated 
imbalance in hepatocyte [NADP
+
]:[NADPH] concentration ratios, since GSH is required for 
the reconversion of NADP
+
 to NADPH.
62
  
 
Additionally, disruption of the NAD
+
/NADP cycle may be linked to the dysregulation of 
lysosomal calcium previously observed In NP-C1 disease.
63
 This lysosomal release of Ca
2+
 
arises from the actions of the Ca
2+
-mobilising second messenger nicotinic acid adenine 
dinucleotide phosphate (NAADP).
63
 Although mechanisms for the biosynthesis of NAADP 
remain speculative, one probable route is the base-exchange process involving reaction of 
NADP with nicotinate to generate both NAADP and niacinamide, which is catalysed by ADP-
ribosyl cyclases.
64
 Since both nicotinate and niacinamide were 
1
H NMR-detectable in this 
study, and both were represented as a significantly downregulated admixed ISB predictor 
variable in the NP-C1 disease classification, we tested for any differences in the hepatic 
molar concentration ratios of niacinamide:nicotinate between the NP-C1 and HET/WT 
classifications. Although this ratio was ca. 47% greater in the NP-C1 group, this difference 
was found not to be statistically significant (p = 0.082).  
 
Consistent with our observations, Waters et al.
34
 also found a downregulation of hepatic 
niacinamide in their 
1
H NMR-linked metabolomics study of thioacetamide-driven 
fibrosis/cirrhosis in experimental animals, and this was ascribed to an enhanced level of this 
metabolite’s methylation to 1-methylnicotinamide in cirrhotic liver. Furthermore, Varela-
Rey et al.
65
 found that orally-administered niacinamide ameliorated fatty liver and fibrosis in 
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glycine N-methyltransferase knockout mice, and concluded that this agent acted through 
the prevention of hepatic fat accumulation and apoptosis via reductions in liver S-
adenosylmethionine content.   
 
In view of the potential far-reaching implications of any disturbances to the NAD
+
/NADP
+
 
cycles, and also to NAADP biosynthesis, it is possible that the statistically significant 
differences in liver metabolite concentrations observed here could be traced back to defects 
in metabolic pathways linked to the early-onset, rapidly progressive form of the clinical NP-
C1 phenotype,
66,67
 which is associated with hepatic dysfunction, together with infantile 
psychomotor delay.
68
 
 
 4.5 3-Hydroxyphenylacetate as a potential biomarker for NP-C1 disease-associated liver 
dysfunction: Intriguingly, the ISB intensity of 3-hydroxyphenylacetate was found to be 
significantly lower in the NP-C1 group than that of the control HET/WT one. Moreover, it 
was found to be strongly associated with a PC also featuring nicotinate and niacinamide, 
together with PEP and the unassigned 0.77-0.80 ppm ISB [Figure 6(b)]. 3-
hydroxyphenylacetate is involved in the human tyrosine metabolism pathway, in which it is 
transformed to 3,4-dihydroxyphenylacetate via the enzyme 4-hydroxyphenylacetate 3-
mono-oxygenase. This reaction also requires NAD
+
/NADH as a coenzyme system (equation 
2), and which is synthesized through the nicotinate/niacinamide pathway, metabolites of 
which were also identified as discriminatory variables here. 
 
3-hydroxyphenylacetate + O2 + NADH + H
+
 ↔ 3,4-dihydroxyphenylacetate + NAD
+
 + H2O        (2) 
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Imbalances in 3-hydroxyphenylacetate biosynthesis may indicate that perturbations in the 
hepatic [NAD
+
]:[NADH] molar concentration ratio (an index of mitochondrial redox status) in 
NP-C1 disease mice, a process favouring oxidative reaction processes in vivo, as noted above 
(section 4.4). Hence, disturbances in the metabolism of 3,4-dihydroxyphenylacetete to 3-
hydroxyphenylacetate (suppressing production of the latter) in mutant NP-C1 disease 
mouse liver tissue may serve to partially conserve oxidising NAD
+ 
equivalents required for 
further metabolic processes, possibly one or more of those required for the upregulation of 
metabolites identified as biomarkers here.  
 
However, the potential applications of 3-hydroxyphenylacetate as a biomarker for NP-C1 
disease-associated liver disease are complicated, since this phenolic acid anion is also 
generated as a co-metabolite arising from gut microflora.
69
 Indeed, this agent appears to 
serve as a valuable marker for bacterial dysbiosis, and has been demonstrated to appear 
when bacteria are introduced to germ-free rats.
70
 Therefore, imbalances in the activity of 
such microflora in mutant NP-C1 disease mice may also account for the significantly lower 
hepatic levels of this metabolite found in this group. Indeed, in a recent study, we found 
that human urinary concentrations of the co-metabolite trimethylamine were significantly 
elevated (> 2-fold) over those of a heterozygous carrier control group, an observation also 
reflecting significant NP-C1 disease-induced modifications to the metabolic activities of gut 
microflora. Moreover, Mardinoglu et al.
71
 found that gut microbiota modulates host amino 
acids and GSH metabolism in mice, observations also relevant to our findings here.  
   
A further complication is that 3-hydroxyphenylacetate may also arise directly from dietary 
sources
72
, and it may be generated from dietary polyphenols which are resistant to the 
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actions of digestive enzymes. Notably, urinary levels of this agent are substantially increased 
when humans are fed catechin and chocolate (the latter being a rich source of 
proanthocyanidin),
73
 and previous investigations employing a human anaerobic fecal 
fermentation model revealed that quercetin was metabolised to 3,4-
dihydroxyphenylacetate within 2 hr., and that the latter metabolite was then transformed 
to 3-hydroxyphenylacetate during a subsequent 8 hr. period.
74
 Hence, these additional 
factors represent further confounding limitations regarding the use of this agent as a 
potential biomarker. Moreover, this metabolite serves as an effective antioxidant, and 
hence its lower hepatic levels observed here conceivably also arise from its oxidative 
consumption by reactive oxygen species (ROS) such as hydroxyl radical (
•
OH).  
 
Previous reports on the value of 3-hydroxyphenylacetate as a biomarker are somewhat 
limited, but in one study Boudonck et. al.
75
 found that this metabolite, together with 
hippurate, served as a progressive downregulated urinary marker of nephrotoxicity in rats 
treated with three distinct nephrotoxins. Indeed, 3-hydroxyphenylacetate concentrations 
were reduced up to 7-fold in these samples, and the researchers involved concluded that 
this biomolecule featured as a very early and valuable biomarker of nephrotoxicity. 
Moreover, abnormal urinary levels of this metabolite have also been reported in both 
eosinophilic esophagitis and gastrointestinal reflux disease
76
.   
 4.6 Metabolism and potential antioxidant (ROS-scavenging) roles of hypotaurine: The role 
of hypotaurine as a potential biomarker for NP-C1 disease-associated liver dysfunction is 
complicated in view of the partial overlap of its C4-CH2SO2
-
 resonance with that of 
methionine’s-C4-CH2 one, as noted above. However, if its role as a biomarker here is 
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confirmed, hypotaurine serves as a key antioxidant defence in mitochondria and further 
intracellular environments, and is oxidised by ROS to yield taurine, which is subsequently 
excreted through its transporter into extracellular media.
77
 The production of ROS has been 
indicated as one of the pathogenic effects arising from NP-C1 disease pathogenesis, and 
consistent with this hypothesis, elevated levels of cholesterol oxidation products have been 
reported in the blood plasma of NP-C1 disease patients, and also in the liver of NP-C1 
mutant mice.
78
 In view of the involvement of oxidative stress in this disease process,
79
 the 
increased hepatic generation of hypotaurine noted here may arise as an essential metabolic 
response stimulated to combat against it.
80
 The diminished GSH:GSSG molar ratios observed 
in NP-C1 mouse livers are also consistent with an elevated level of hepatic oxidative stress in 
this animal model (section 4.7).  
 
Several previous studies performed in NP-C1-deficient mice indicate that hepatocyte 
apoptosis may serve as a primary cause of progressive liver degeneration and failure in this 
animal model,
8,36
 and/or an increased activation of macrophages
10
; such considerations may 
also be applicable to human NP-C1 patients.  If confirmed, higher NP-C1 hepatic hypotaurine 
levels observed may be consistent with an enhanced metabolism of cysteine by the hepatic 
cysteine dioxygenase/cysteine sulphinate decarboxylase pathway stimulated by an 
upregulation of oxidative stress episodes, which serve as key mediators of hepatocyte 
apoptosis. However, with regard to macrophage activation, we found no evidence for NP-C1 
disease-mediated increases in levels of nitric oxide (NO
•
)-producing arginine in the NP-C1 
mutant classification liver samples.  
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4.7 Imbalances in hepatic GSH/GSSG redox status in NP-C1 disease mice: The reduced 
hepatic [GSH]:[GSSG] molar ratios observed in the NP-C1 mouse model are consistent with 
the development of liver fibrosis as a pathological feature. Indeed, it is well known that 
tissue GSH concentrations significantly diminish in both experimental fibrosis models and in 
human fibrotic diseases, although the precise mechanism and biological significance of 
these depletions remain unclear.
81
 Although there is also much evidence available indicating 
that such changes in hepatic GSH levels arise from an increased level of ROS-mediated 
oxidative stress
82
 (which itself appears to play an important role in the development of 
fibrotic diseases in humans), alternative hypotheses are that it may also be ascribable to a 
dysregulation of the synthesis of this small molecule antioxidant during liver injury/fibrosis, 
or more simply the availability of cysteine, which may be limited in view of nutritional 
deficiencies and/or multiple perturbations to the methionine metabolic pathway.
83
 Hence, 
results from these studies are consistent with the upregulations of hepatic phenylalanine, 
threonine, tyrosine, methionine and valine observed in this study. 
 
4.8 Perturbations to hepatic PEP concentrations in NP-C1 disease mice: PEP is generated 
via the actions of the enzyme enolase on 2-phosphoglycerate, and subsequently it is 
metabolised to pyruvate by pyruvate kinase, a process yielding ATP through substrate level 
phosphorylation (these represent the 9th and 10th step of the glycolysis pathway, 
respectively)
84
. However, in gluconeogenesis, PEP is produced from oxaloacetate 
decarboxylation, a process which involves the hydrolysis of guanosine triphosphate (GTP)
84
. 
This reaction is the rate-limiting stage of this process, and is catalysed by PEP carboxykinase 
(PEPCK).  Therefore, disturbances to either of these pathways (specifically, malfunctions in 
the above enzymes, and particularly that involved in the rate-determining step of   
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gluconeogenesis) may indeed have some profound consequences regarding hepatic 
function and integrity in this NP-C1 disease mouse model.   
   
4.9 Inosine as a potential biomarker feature: Inosine is hepatically-metabolised, and arises 
from the transformation of adenine to adenosine or inosine monophosphate (IMP), each of 
which may then be converted to inosine
84
. Moreover, the enzyme purine nucleoside         
phosphorylase intra-converts inosine and hypoxanthine. Notably, inosine has not been 
previously reported as a biomarker for fibrosis-cirrhosis, nor non-specific liver dysfunction 
or failure, and hence its diminished hepatic concentrations may arise as a consequence of   
NP-C1 disease pathology. Moreover, inosine also serves as an essential intermediate in a 
chain of purine nucleotide reactions which are involved in muscle movement. In a mouse 
model of septic shock, intraperitoneally-administered inosine has been found to alleviate 
systemic inflammation, organ damage, vascular dysfunction and tissue hypoxia
85
. Indeed, in 
these studies, inosine administration was also found to elevate the hepatic [NAD
+
]:[NADH] 
ratio, which serves as an index of mitochondrial redox status
86
. Therefore, the lower hepatic 
levels of inosine detectable in NP-C1 mice may again be consistent with imbalances in this 
ratio.  
    
5. CONCLUSIONS 
 
1
H NMR-linked metabolomics techniques provide much valuable biomolecular information   
reflecting hepatic dysfunction or damage in the NP-C1 disease mouse model system, 
including the development of fibrosis. Although many of our observations are generally   
consistent with the development of fibrosis-cirrhosis (or alternative liver dysfunctions) in 
Page 35 of 65
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
36 
 
NP-C1 mice (i.e. increased hepatic levels of selected amino acids such as AAAs and 
glutamate, together with diminished GSH and niacinamide concentrations), it appears that 
upregulated lysine/ornithine, and downregulated 3-hydroxyphenylacetate, PEP and inosine, 
are not. Contingent disturbances to the 
1
H NMR metabolic profiles of human biofluids (e.g., 
blood plasma or urine) could, at least in principle, be employed to monitor the aetiology, 
pathogenesis and severity of liver damage in NP-C1 patients. Our observations are 
consistent with modifications to the blood plasma amino acid patterns of both humans and 
experimental animals which are induced by chronic liver failure, specifically elevated 
concentrations of tyrosine and phenylalanine, in addition to that of methionine. 
Downregulation in the hepatic nicotinate/niacinamide concentrations observed here could 
be linked to dysfunctions in the NAD
+
/NADH cycle and the biosynthesis of Ca
2+
-mobilising 
second messenger NAADP which may, at least in principle, exert a substantial range of 
physiological effects, and also be associated with further metabolic disturbances observed 
in NP-C1 disease mice. 
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Figure Legends 
Figure 1. 
1
H-NMR spectra of an aqueous extract of an NP-C1 disease liver biopsy sample 
from a female mouse collected at 9 weeks. A typical spectrum is shown. Abbreviations: 1, 
Unassigned-1; 2, Leu-CH3/Ile-C5-CH3/Val-CH3a; 3, 2-Aminobutyrate-CH3; 4, Val-CH3b; 5, 
Propylene glycol-CH3; 6, Lactate-CH3; 7, Alanine-CH3; 8, Lys-C5-CH2/Orn-C4-CH2; 9, Acetate-
CH3; 10, Acetonitrile; 11, Met-CH3; 12, GSSH-Glu-C3-CH2/Gln-C3-CH2; 13, Glu-C4-CH2; 14, 
Oxalacetate-CH2; 15, Succinate-CH2; 16, Gln-C4-CH2; 17, Met-C4-CH2/Hypotaurine-C4-CH2; 
18, Asp-CH2a; 19, Sarcosine-CH3; 20, Asp-CH2b; 21, TMA-CH3’s; 22, Dimethylglycine-CH3’s; 23, 
GSSH-Cys-C3-CH2; 24, Creatine-CH3; 25, Lys-C6-CH2; 26, Orn-C5-CH2; 27, 
Choline/Phosphocholine-CH3’s; 28, Glycerophosphocholine-CH3’s; 29, Taurine-S-CH2/β-
Glucose-C2-CH; 30, Methanol; 31, β/α-Glucose-C4-CH; 32, Taurine-N-CH2; 33, β-Glucose-
C3/5-CH; 34, Glycine; 35, Glycerol-C1/3-CH2; 36, β-Glucose-C6-CHa/α-Glucose-C3-CH/6-CH2; 
37, β-Glucose-C6-CHb; 38, Betaine-CH2; 39, Lactate-CH2; 40, Thr-CH2; 41, Ascorbate; 42, GSH-
Cys-CH; 43, β-Glucose/Glucose-6P-C1-CH; 44, Phosphoenolpyruvate-CH2a; 45, α-
Glucose/Glucose-6P-C1-CH; 46, Phosphoenolpyruvate-CH2b/Glycogen; 47, Uracil-CO-CH; 48, 
GTP-C1’-CH; 49, 3-Hydroxyphenylacetate-CH2; 50, Tyr-C2/6-CH; 51, Tyr-C3/5-CH; 52, 3-
Hydroxyphenylacetate-C4/6-CH; 53, Phenylalanine; 54, Uracil-NH-CH; 55, Niacinamide-C5-
CH; 56, Guanosine-C8-CH; 57, GTP/GMP-C8-CH; 58, GMP-C8-CH/Hypoxanthine-C2-CH; 59, 
Hypoxanthine-C8-CH; 60, Nicotinate-C4-CH; 61, Nicotinate/Niacinamide-C6-CH; 62, 
Nicotinate/Niacinamide-C2-CH. 
Figure 2. (a) Three-Dimensional (3D) PC4 vs.PC3 vs. PC2 scores plot arising from PCA of the 
preliminary (complete) dataset with P = 136 ISB predictor (X) variables. Key: WT, red 
squares; NP-C1, yellow diamonds; and HET, green circles. (b) Multidimensional scaling plot 
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of a random forest proximity matrix from HET/WT vs NP-C1 analysis demonstrating the 
success of discrimination from a single RFs iteration. 
Figure 3. (a) Three-Dimensional (3D) component 3 vs. component 2 vs. component 1 scores 
plot arising from PLS-DA of the liver sample dataset incorporating only the 3- and 9-week 
time-point samples for both the NP-C1 and HET/WT classifications [with P = 136 ISB 
predictor (X) variables]; (b) O-PLS-DA plot of orthogonal T score vs. T score for this 3- and 9-
week time-point dataset; (c) Permutation testing plot for the R
2
Y and Q
2
 values determined 
from this analysis.  
Figure 4. Box plots of TSP-normalised ISB resonance intensities of the 12 metabolites 
identified as discriminatory variables by RFs analysis vs. time-point (weeks) for the NP-C1 
(grey) and HET/WT (white) phenotypic classifications. 
 
Figure 5. (a) ROC curves for the RFs models developed. Combinations of variables gave rise 
to AUROC values ranging from 0.801 for 2 variables, to 0.941with 12 variables, as indicated 
in the lower right-hand inset. (b) Predictive accuracies as a function of increasing numbers 
of biomarker variables employed for constructing the RFs model. 
 
Figure 6. (a) 2D PCA scores plot of PC2 versus PC1 (which account for a cumulative variance 
of 70.6%) for a model incorporating only the most significant RFs-determined 12 biomarker 
metabolites; (b) Corresponding loadings plot for these biomarkers for the combined NP-C1 
and HET/WT dataset: glutamate, hypotaurine/methionine, valine, lysine/ornithine, tyrosine 
and phenylalanine all had highly positive PC1 and weakly negative PC2 loadings, whereas 
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nicotinate/niacinamide, inosine, 3-hydroxyphenylacetate and the unassigned δ = 0.77-0.80 
ppm resonance had highly positive PC2 with low or intermediately-positive PC1 ones.  
 
Figure 7. Venn diagram showing similarities and differences in biomarker candidates 
(detected in NP-C1 disease mutant mouse model liver, human and mutant mouse model 
blood plasma/serum, and human urine) between this study and those previously 
reported.
14,49,78,87-93
. Abbreviations: Lyso-SM-509, lyso-sphingomyelin-509; MCs, 
monohexosylceramides; LGALS3, galectin-3; CTSD, cathepsin D; 3-AIB, 3-aminoisobutyrate; 
3-HPA, 3-hydroxyphenylacetate; PEP, phosphoenolpyruvate; 2PY and 4PY, N-methyl-2-
pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide respectively; *this study. 
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Figure 1. 
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Figure 2.   
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Figure 3(a) 
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Figure 3(b) 
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Figure 3(c) 
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Figure 4.  
 
Figure 5.  
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Figure 6. 
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Figure 7.  
 
 
 
 
 
 
 
 
BLOOD PLASMA/SERUM (NP-C1 MUTANT 
MOUSE MODEL AND HUMAN): 
7-Ketocholesterol (↑)78,87; 3β,5α,6β-Chloestane-triol (↑)78,87; 
LGALS3 (↑)88; CTSD (↑)88; Chitotriosidase (↑)89; 
Lysosphingomyelin (↑)90; Lyso-SM-509 (↑)91; Ceramides 
(↑)49
LIVER (NP-C1 MUTANT MOUSE 
MODEL):
Phe (↑)*; Tyr (↑)*; HTau/Met (↑)*; 3-HPA (↓)*; 
Lys/Orn (↑)*; PEP (↓)*; Thr (↑)*; Glu (↑)*; 
Inosine (↓)*; Niacinamide/Nicotinate (↓)*; GM2 
Gangliosides (↑)49
URINE (NP-C1 HUMAN):
3-AIB (↑)14; 3-HIB (↑)14; Bile acids (↑)14; 
Quinolinate (↑)14; Ile (↑)14; Trigonelline (↓)14; 
NMN amide (↓)14; Gln14 (↑); Ala (↑)14; 2-
Hydroxyglutamate (↓)14 ; 2-Hydroxy-3-
methylbutyrate (↓)14 ; Nicotinamide riboside 
(↑)14; 2PY (↓)14; 4PY (↓)14; 3-Methylhistidine 
(↑)14; TMA (↑)14; Suc (↑)14;  Pyroglutamate (↑)14; 
N-Acetylsugars (↑)14; Propane-1,2-diol (↑)14; 3β-
Sulfoxy-7β-N-acetylglucosaminyl-5-cholen-24-
oate and its glycine and taurine conjugates (↑)92; 
3β,7β-Dihydroxy-5-cholen-24-oate and its glycine 
and taurine conjugates (↑)93
Val (↑)14; 
Nicotinate (↓)14  
MCs (↑)49; 
Sphingoid 
bases (liver↑, 
plasma↓)49  
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Tables 
 Collection Time-Point (weeks) 
Disease Class 3  6  9  11  3  6  9  11  3  6  9  11  
WT 3 3 3 3 3 3 5 5 6 6 8 8 
HET 3 3 4 5 3 3 5 5 6 6 9 10 
NP-C1 3 3 5 3 3 4 6 3 6 7 11 6 
 Female Male Total 
 
Table 1. Liver samples available for 
1
H NMR-linked metabolomics analysis at time-points of 
3, 6, 9 and 11 weeks.  
 
 
Variable 
Ranking 
ISB (ppm) Multiplicity Assignment 
Fold 
change 
'Between-disease 
classifications’ 
ANCOVA p-value 
1 7.30-7.35 d (6.8) Phenylalanine-C1/C2-CH 1.74 2.73x10
-7
 
2 7.17-7.23 d (8.6) Tyrosine-C3/C5-CH 1.58 9.48x10
-8
 
3 7.35-7.39 m Phenylalanine-C3/4/5-CH 3.49 9.63x x10
-4
 
4 0.94-1.00 d (7.1) Valine-CH3 1.54 1.22 x10
-6
 
5 2.62-2.67 m Hypotaurine-C4-CH2SO2
-
/Methionine-C4-CH2 1.87 1.48x x10
-3
 
6 6.78-6.81 m 3-Hydroxyphenylacetate-C4-CH
 
-2.94 5.78 x10
-6
 
7 2.99-3.05 t/t Lysine-C6-CH2/Ornithine-C5-CH2 1.49 6.91 x10
-5
 
8 6.86-6.93 d (8.2) Tyrosine-C2/C6-CH 2.05 1.01 x10
-3
 
9 5.16-5.21 t (1.1) PEP-CH2a -1.74 0.027 
10 0.77-0.80 t (7.5) Unassigned -1.27 0.055 
11 4.24-4.30 m Threonine-C3-CH 1.32 2.95 x10
-4
 
12 2.32-2.40 m Glu-C4-CH 1.38 1.032 x10
-3
 
13 1.68-1.74 m/m Lysine-C5-CH2/Ornithine-C4-CH2 1.42 1.21 x10
-4
 
14 8.32-8.36 s Inosine-C2-CH -1.75 2.86 x10
-3
 
15 8.23-8.29 dd Nicotinate/Niacinamide-C4-CH -1.28 0.037 
 
 
Table 2. Key 
1
H NMR ISB biomarker variable features derived from application of MV RFs 
analysis: ISB variables are ranked from 1 to 15 based on their MDA values. 'Between-disease 
classifications’ ANCOVA p values and fold-changes are also provided. 
1
H NMR resonances, 
their coupling patterns and assignments were confirmed via the methods outlined in section 
2.4. Positive fold change values indicate upregulations in NP-C1 disease, whereas negative 
ones indicate a higher level determined in the HET/WT group.  
 
 
 
 
 
 
Page 63 of 65
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
64 
 
 
Metabolic Pathway 
Total 
Compounds 
Hits FDR Impact 
Tyrosine  biosynthesis 4 2 4.60 x 10
-6
 1 
Glutamine and glutamate metabolism 5 1 0.0024 1 
Phenylalanine metabolism 11 2 4.60 x 10
-6
 0.4074 
Alanine, aspartate and glutamate metabolism 24 1 0.0024 0.2595 
Nicotinate and nicotinamide metabolism 13 2 0.3715 0.2381 
Tyrosine metabolism 44 1 6.51 x 10
-6
 0.1405 
Glycolysis or Gluconeogenesis 26 1 0.0052 0.1039 
Arginine and proline metabolism 44 1 0.0024 0.0935 
Glutathione metabolism 26 1 0.0024 0.0553 
Purine metabolism 68 1 0.0077 0.0026 
 
Table 3. Matched metabolic pathways and pathway impact values arising from quantitative 
pathway enrichment analysis and pathway topology analysis respectively. The FDR-adjusted 
p values of these significant pathway features are also provided.   
 
 
 
Metabolite Upregulation (↑) 
or 
Downregulation 
(↓): this study 
Biomarker status in 
Fibrosis-Cirrhosis 
(Upregulation or 
Downregulation)
33-35 
Biomarker Status in 
Further Liver 
Disease/ 
Toxicological 
Damage
43 
Glutamate ↑ Yes (↑) Yes (↑) 
Hypotaurine ↑ No No 
Methionine ↑ Yes (↑) No 
Threonine ↑ No Yes (↑) 
Lysine ↑ No No 
Ornithine ↑ No No 
Valine ↑ No Yes (↑) 
Phenylalanine ↑ Yes (↑) Yes (↑) 
Tyrosine ↑ Yes (↑) Yes (↑) 
3-Hydroxyphenylacetate ↓ No No 
Phosphoenolpyruvate ↓ No n-d 
Inosine ↓ Yes (↑) n-d 
Niacinamide ↓ Yes (↓) n-d 
Nicotinate ↓ No n-d 
 
Table 4. Summary of the biomarker status of the significant predictor metabolite variables 
detected in this investigation in fibrosis-cirrhosis development
33-35
, and also in further liver 
disease/hepatic toxicity
43
 investigations reported. Abbreviations: n-d, not determined.     
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NP-C1 Mutant (Npc1-/-; NP-C1) Mouse 
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